Clinical trial NCT02489786: A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital
Official title: A Prospective Randomized Study of Different Digoxin Treatment Regimens in Egyptian Hospital
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Atrial Fibrillation
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2015-07-03
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Digoxin is the primary cardiac glycoside in clinical use. Because of the narrow therapeutic index and risk of toxicity, therapeutic drug monitoring is highly recommended. In Egypt, most cardiologists give digoxin holiday for both atrial fibrillation and heart failure, it is not clear if the interrupted digoxin regimens are effective since serum digoxin concentrations might fall below the therapeutic range.

Objective: To evaluate and compare the digoxin serum concentration and patient's quality of life in the continuous versus interrupted digoxin dosing regimens.

Detailed description: Digoxin is a cardiac glycoside prescribed in heart failure and certain supraventricular tachyarrhythmias. It exerts a positive inotropic, neurohormonal, and electro physiologic actions on the heart . For heart failure patients, the targeted steady state serum digoxin level is between 0.5 and 0.8 ng/ml . Ventricular rate control in atrial fibrillation patients will usually require higher digoxin steady state serum concentrations . However, serum digoxin level higher than 2 ng/ml is associated with increased incidence of adverse drug reactions and should be avoided . Because of inter and intra-patient variability, narrow therapeutic index, and risk of toxicity, digoxin doses are calculated based on the patient weight, renal status, indications and drug interactions. Due to substantial overlap between therapeutic and toxic levels of digoxin, therapeutic drug monitoring is a must especially in patients with deteriorating renal function and electrolyte disturbance. In Egypt, most cardiologists give a digoxin holiday for patients with atrial fibrillation and /or heart failure where patients skip the drug doses on Thursday and Friday or Friday only every week to avoid possible drug accumulation and toxicity. It is not clear if these interrupted digoxin regimens really offer safer alternative over the continuous dosing regimens without compromising the effectiveness. It is anticipated that plasma digoxin levels may fall below the therapeutic range during the holiday which may affect patient clinical status and quality of life.

Eligibility criteria: Inclusion Criteria:

* Patients with atrial fibrillation (AF)
* with or without congestive heart failure (CHF)
* taking digoxin tablets with or without holiday regimens

Exclusion Criteria:

* taking the following drugs concurrently: amiodarone, verapamil, quinidine and propafenone.
* diagnosed with thyroid disorders (hyperthyroidism \& hypothyroidism).
* diagnosed with renal failure
* pregnant

Primary outcomes:
measure: measuring digoxin trough steady state plasma concentrations for the interrupted and continuous treatment regimens
timeFrame: 1 month
Secondary outcomes:
measure: evaluating patients quality of life using quality of life questionnaire for atrial fibrillation patients
timeFrame: 1 month
measure: evaluating signs and symptoms of digoxin side effects and toxicity by using specific structured questions
timeFrame: 1 month
Other outcomes:
Locations:
Study officials:
References: